About: Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

clinical trial

Attributes	Values
rdf:type	Item
description	clinical trial (en) ensayu clínicu (ast) klinisch onderzoek (nl) клінічне випробування (uk)
rdfs:label	Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (en)
skos:prefLabel	Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (en)
name	Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (en)
title	wds:Q64710519-B103C7BA-B265-47FE-9042-9CA5EF680ED0
title	A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (en)
end time	wds:Q64710519-4BC69119-CBFD-4EF3-86B7-3B3D574E7C1B
end time	2012-03-01 00:00:00Z (xsd:dateTime)
instance of	wds:Q64710519-6622EC04-BDAB-44CD-BC51-FC03EE9419B6
instance of	clinical trial
start time	wds:Q64710519-EF2EE991-FEF3-4DAF-8FEC-F6BC9DC7F7F6
start time	2008-12-01 00:00:00Z (xsd:dateTime)
country	wds:Q64710519-1CC1C06F-D92D-48B0-8AD9-3477EF3B4BE1 wds:Q64710519-966F78A6-45D5-4C6E-B2D3-6C67108FA116
country	Malawi United States of America
research site	wds:Q64710519-0BE89E43-12C2-4083-9602-967C8DA83E22 wds:Q64710519-139447BC-2935-4ED4-9468-1AD36A4BEB0D wds:Q64710519-18ADD906-E0D4-4FCA-A1B5-59D4A2E2E0D4 wds:Q64710519-1AC57359-E07A-43AA-898D-181A7799FFC4 wds:Q64710519-1D0EF1B1-ADD3-4607-8F21-43BFC58350F3 wds:Q64710519-2AC6C831-F5C0-495D-A14B-0BF33A1484D0 wds:Q64710519-31763131-B358-4596-8DAC-117BFB715CD2 wds:Q64710519-36302A86-11F6-4B20-8477-4BB51123329D wds:Q64710519-3B6C8B51-E2D4-46BF-9910-9F25F6B12323 wds:Q64710519-47159A0E-E47A-4D6F-9162-6DEFD672863A wds:Q64710519-57270FFC-7532-41EF-8DED-F61DC5B0ED41 wds:Q64710519-5D61494A-0DC3-4824-A51F-9BE0BDCEDD22 wds:Q64710519-8E37C2C5-9DCC-42A9-B407-314F98FFAA26 wds:Q64710519-93E43046-C153-40CD-BC2D-F6F81F23E885 wds:Q64710519-A6DA5358-885D-425E-BC77-1B6FC47FA508 wds:Q64710519-AE6FC9A0-82CD-4680-BB66-D6E0BD6029DD wds:Q64710519-E33D7F17-E43A-4EA9-9EA8-2369489021D6 wds:Q64710519-EBE11560-2308-4ED4-92D9-F41974E31DDF wds:Q64710519-ECA3791E-B88C-45D1-AE77-2BE196EC3EA0 wds:Q64710519-FCC16FE2-9A09-4099-9800-BE79860A6C8B wds:Q64710519-FEB57B20-DF6F-4381-B6D0-BAA6CF4E8A78
research site	University of Florida University Health Truman Medical Center University of North Carolina at Chapel Hill Washington University in St. Louis University of Rochester Boston University Mayo Clinic University of Kansas Medical Center Massachusetts General Hospital Rush University Medical Center NewYork–Presbyterian Hospital University of Alabama at Birmingham Vanderbilt University Medical Center University of Virginia Cleveland Clinic University of Louisville University of South Florida Medical College of Wisconsin Dartmouth University Shafran Gastroenterology Center Atlanta Gastroenterology Associates
short name	wds:Q64710519-A28CE1A7-9212-4FC8-BD2E-6390BBA23894
short name	GEMINI II (en)
research intervention	wds:Q64710519-C09FFB7E-CB32-4C63-93D2-9B2B0DC69DFD
research intervention	vedolizumab
minimum age	wds:Q64710519-EA5B61EA-7DCA-454C-8ADE-A98B1FBC45C6
minimum age	18 (xsd:decimal)
located in the adm...erritorial entity	wds:Q64710519-5D1854B3-FF74-40F7-BB21-67A99C23E8B6
located in the adm...erritorial entity	Puerto Rico
number of participants	wds:Q64710519-5E57F166-D720-484B-B629-3C62117FFB71
number of participants	1116 (xsd:decimal)
maximum age	wds:Q64710519-87B59DE8-D04C-43D1-97D2-4012705A46E6
maximum age	80 (xsd:decimal)
study type	wds:Q64710519-9737935A-83E4-42D0-9427-F8AD798B913E
study type	interventional study
ClinicalTrials.gov ID	wds:Q64710519-C916481B-9914-4789-9530-C6C902840E17
ClinicalTrials.gov ID	NCT00783692
clinical trial phase	wds:Q64710519-0FD5D19A-3301-4A1C-B73F-F8DFD2FC8929
clinical trial phase	phase III clinical trial
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q64710519

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software